Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 73.6 per share, up from the previous target of HKD 59.15 [7]. Core Insights - The company has significantly raised its guidance for the drug Naisukan, expecting sales to reach RMB 12-14 billion in 2025, with continued high growth projected for 2026 at RMB 24-26 billion [2]. - The company reported a revenue of RMB 4.46 billion for the first half of 2025, marking a 48% year-on-year increase, with a notable reduction in non-IFRS losses by 31% [1]. - The company is focusing on innovative products with differentiated competitive advantages, particularly in the fields of anti-infection and kidney disease treatments [7]. Summary by Sections Naisukan Performance - Naisukan achieved sales revenue of RMB 3.03 billion in H1 2025, representing an 81% year-on-year growth, with August sales reaching RMB 5.20 billion [2]. - The drug was successfully commercialized in mainland China in May 2024 and included in the medical insurance directory in November 2024 [2]. Other Drug Developments - The drug Yijia generated revenue of RMB 1.43 billion in H1 2025, a 6% increase, with a 37% growth in direct sales to hospitals [3]. - EVER001 (Hibutinib) is showing promising clinical trial results, positioning it as a potential best-in-class product for broad-spectrum autoimmune kidney diseases [4]. Clinical Trials and Approvals - The drug Aiqumide has completed a significant clinical study in Asia and is expected to receive approval in mainland China by H1 2026 [5]. - The company is advancing its mRNA technology platform, with the EVM16 personalized cancer vaccine having completed its first patient dosing and EVM14 receiving FDA IND approval [6]. Financial Projections - The company has revised its revenue forecasts for 2025-2027 to RMB 17.38 billion, RMB 28.69 billion, and RMB 33.51 billion respectively, reflecting the strong performance of Naisukan and the anticipated approval of Aiqumide [7].

Core Points - CloudTop New Horizon (01952) announced that on September 2, 2025, employees (excluding directors) exercised stock options under the post-IPO employee stock option plan, resulting in the issuance of 1,257 shares [1] - On September 5, 2025, the company issued 2.6061 million shares according to the pre-IPO employee stock option plan adopted on December 25, 2018 (revised and restructured on February 17, 2020) and the post-IPO share award plan adopted on September 21, 2020 [1]

Group 1 - Company announced the issuance of 1,257 shares on September 2, 2025, under the post-IPO employee stock option plan [1] - On September 5, 2025, the company issued 2.6061 million shares based on the pre-IPO employee stock option plan adopted on December 25, 2018, and revised on February 17, 2020, as well as the post-IPO share award plan adopted on September 21, 2020 [1]

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01952 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | | 於下列日期開始時的結存(註1) | 2025年8月31日 | | 350,928,043 | | 0 | | | 350,928,043 | | 1). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 而發行新股或轉讓庫存股份 - 涉及新股 | | | 1,257 | 0.0004 % ...

[Company Information](index=3&type=section&id=%E5%85%AC%E5%8F%B8%E8%B3%87%E6%96%99) This section provides essential corporate details, including governance, key personnel, and identifying information [Company Basic Information](index=3&type=section&id=%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E4%BF%A1%E6%81%AF) This section provides an overview of Everest Medicines' fundamental details, including governance, key personnel, and corporate identifiers - Joint Company Secretary Ms. Liu Xuxin resigned on **April 15, 2025**, with Mr. Yang Jinghang appointed concurrently[4](index=4&type=chunk) - The company's auditor is **Ernst & Young**[4](index=4&type=chunk) - The company's stock code is **1952**, and its website is **www.everestmedicines.com**[5](index=5&type=chunk) [Business Summary](index=5&type=section&id=%E6%A5%AD%E5%8B%99%E6%91%98%E8%A6%81) This section highlights the company's strategic advancements, significant sales growth, and pipeline progress across key therapeutic areas [Overall Business Overview](index=5&type=section&id=%E6%95%B4%E4%BD%93%E4%B8%9A%E5%8B%99%E6%A6%82%E8%A7%88) The company significantly grew sales revenue and advanced its innovative pipeline by deepening its "dual-driver" strategy and strengthening its Asian market presence - The company deepened its **"dual-driver" strategy**, achieving significant sales revenue growth and smooth progress in its innovative product pipeline[6](index=6&type=chunk) - Three commercialized products cover kidney, infectious, and autoimmune diseases, with estimated combined peak sales revenue exceeding **RMB 10 billion**[6](index=6&type=chunk) - Nefecon® is included in the **NRDL** and received **full NMPA approval**, leading to rapid sales growth[6](index=6&type=chunk) [Renal Pipeline](index=5&type=section&id=%E8%85%8E%E7%97%85%E7%AE%A1%E7%B7%9A) Nefecon®, a key product for IgA nephropathy, received full NMPA approval and NRDL inclusion, enhancing patient access, while EVER001 showed positive efficacy and safety in its Phase 1b/2a trial for primary membranous nephropathy - Nefecon® implemented new medical insurance pricing in **January 2025**, enhancing patient accessibility[8](index=8&type=chunk) - In **May 2025**, Nefecon® received **full NMPA approval**, removing proteinuria restrictions and becoming the first and only fully approved causal treatment for IgA nephropathy[9](index=9&type=chunk) - EVER001 (sibrotuzumab) Phase 1b/2a trial showed anti-PLA2R autoantibody reduction of approximately **93%** at 24 weeks, significant proteinuria decrease, stable renal function, and good safety[12](index=12&type=chunk) - Nefecon® production expansion approval will boost capacity to meet growing clinical demand in China and Asia more efficiently[13](index=13&type=chunk) [Infectious Disease Pipeline](index=8&type=section&id=%E6%84%9F%E6%9F%93%E6%80%A7%E7%96%BE%E7%97%85%E7%AE%A1%E7%B7%9A) The in vitro susceptibility testing standard for Eravacycline (Yijia®) was published, guiding clinical use, while EVER001's Phase 1b/2a trial reaffirmed positive efficacy and safety in primary membranous nephropathy - In **June 2025**, the "Eravacycline In Vitro Drug Susceptibility Testing Guidelines (2025)" were published, standardizing testing and interpretation[15](index=15&type=chunk) - EVER001 Phase 1b/2a interim data showed anti-PLA2R autoantibody reduction maintained above **93%**, proteinuria levels decreased to **76.7%** and **80.6%** at 36 weeks, and high immunological complete remission rates[16](index=16&type=chunk) [Autoimmune Disease Pipeline](index=9&type=section&id=%E8%87%AA%E8%BA%AB%E5%85%8D%E7%96%AB%E6%80%A7%E7%96%BE%E7%97%85%E7%AE%A1%E7%B7%9A) Etrasimod for ulcerative colitis demonstrated long-term safety and significant clinical benefits in global 4-year follow-up and Asian Phase III studies, gaining approval in Hong Kong, acceptance in Korea and Taiwan, and initiating local production - Etrasimod's global 4-year safety follow-up data confirmed good long-term safety and tolerability[19](index=19&type=chunk) - Etrasimod's Asian multi-center Phase III study showed significant clinical and endoscopic benefits, with consistent safety profiles[20](index=20&type=chunk) - Etrasimod Jiaxing factory production project launched, with an estimated annual capacity of **50 million tablets** upon operation[20](index=20&type=chunk) - In **April 2025**, Etrasimod received formal marketing approval from the Hong Kong Department of Health, China[20](index=20&type=chunk) - Etrasimod was strongly recommended in the **"2025 ACG Clinical Guidelines: Adult Ulcerative Colitis"** for moderate to severe active UC induction and maintenance[20](index=20&type=chunk) [mRNA Technology Platform](index=10&type=section&id=mRNA%E6%8A%80%E8%A1%93%E5%B9%B3%E5%8F%B0) The company established a leading AI+mRNA platform, advancing mRNA therapeutic cancer vaccines and self-generating CAR-T projects, with EVM16 in clinical trials, EVM14 gaining US FDA IND approval and China NMPA acceptance, and the CAR-T platform showing preclinical efficacy - The company developed an **AI-driven "Miaosuan" neoantigen algorithm**, advancing mRNA therapeutic cancer vaccines and self-generating CAR-T platforms[21](index=21&type=chunk) - Personalized therapeutic cancer vaccine **EVM16** completed first patient dosing and has dosed **nine patients** at Peking University Cancer Hospital[7](index=7&type=chunk)[23](index=23&type=chunk) - Universal therapeutic cancer vaccine **EVM14** IND application received **US FDA approval** and **China NMPA acceptance**, with clinical sample production completed[7](index=7&type=chunk)[23](index=23&type=chunk) - The self-generating CAR-T platform was validated in humanized mouse and non-human primate models, offering off-the-shelf, lymphodepletion-free, and dose-controllable advantages[21](index=21&type=chunk) [Corporate Development](index=11&type=section&id=%E5%85%AC%E5%8F%B8%E7%99%BC%E5%B1%95) The company removed its 'B' share designation, reflecting enhanced R&D and commercialization, successfully raised approximately HKD 1.55 billion for pipeline and commercialization acceleration, and became I-Mab's largest shareholder with a 16.1% stake, deepening its oncology immunotherapy strategy - In **April 2025**, the "B" designation was removed from Everest Medicines' stock short name, reflecting enhanced R&D, commercialization, and overall business fundamentals[28](index=28&type=chunk) - In **July 2025**, the company raised approximately **HKD 1.55 billion** through a placing of **22,561,000 shares**, with several times oversubscription[28](index=28&type=chunk) - In **August 2025**, the company strategically increased its stake in I-Mab to approximately **16.1%**, becoming its largest shareholder[28](index=28&type=chunk) [Financial Highlights](index=12&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) This section presents key financial performance indicators, including revenue growth, margin changes, and adjusted loss, based on IFRS and non-IFRS measures [IFRS Figures](index=12&type=section&id=%E5%9C%8B%E9%9A%9B%E8%B2%A1%E5%8B%99%E5%A0%B1%E5%91%8A%E6%BA%96%E5%89%87%E6%95%B8%E5%AD%97) For the six months ended June 30, 2025, revenue significantly increased by 48.0% to RMB 446.1 million, driven by Nefecon® and Yijia® growth, while gross margin decreased due to Nefecon®'s NRDL price adjustment, R&D expenses were optimized, and distribution and selling expenses rose with market expansion 2025 H1 Key Financial Data (IFRS) | Indicator | 2025 H1 (RMB million) | 2024 H1 (RMB million) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 446.1 | 301.5 | 48.0% | | Gross Margin | 67.1% | 76.6% | -9.5% | | Gross Margin (excl. intangible asset amortization) | 76.4% | 83.0% | -6.6% | | R&D Expenses | 195.2 | 253.2 | -22.9% | | G&A Expenses | 110.8 | 87.0 | 27.4% | | Distribution and Selling Expenses | 314.7 | 200.4 | 57.0% | - Revenue growth was primarily driven by the sustained growth of **Nefecon®** and **Yijia®** in commercialized markets[30](index=30&type=chunk) - Gross margin decreased primarily due to **Nefecon®'s NRDL price reduction** in mainland China and optimized product costs[32](index=32&type=chunk) [Non-IFRS Measures](index=13&type=section&id=%E9%9D%9E%E5%9C%8B%E9%9A%9B%E8%B2%A1%E5%8B%99%E5%A0%B1%E5%91%8A%E6%BA%96%E5%89%87%E8%A8%88%E9%87%8F) For the six months ended June 30, 2025, adjusted loss significantly narrowed to RMB 146.9 million, and loss for the period substantially decreased to RMB 249.8 million, driven by strong product sales, improved operational efficiency, and the one-time impact of mRNA COVID-19 vaccine-related intangible asset impairment loss in the prior year 2025 H1 Non-IFRS Key Financial Data | Indicator | 2025 H1 (RMB million) | 2024 H1 (RMB million) | YoY Change (RMB million) | | :--- | :--- | :--- | :--- | | Adjusted Loss for the Period | (146.9) | (212.6) | 65.7 (narrowed) | | Loss for the Period | (249.8) | (632.4) | 382.6 (decreased) | - Total operating expenses as a percentage of sales decreased by **40.1 percentage points**, reflecting improved business and operational efficiency and focused resource allocation[36](index=36&type=chunk) - As of **June 30, 2025**, cash and cash equivalents and bank deposits totaled **RMB 1,585.9 million**[36](index=36&type=chunk) [Management Discussion and Analysis](index=14&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E5%8F%8A%E5%88%86%E6%9E%90) This section provides a comprehensive review of the company's operational performance, product pipeline, commercialization strategies, and financial results for the period [Overview](index=14&type=section&id=%E6%A6%82%E8%A7%88) As an integrated biopharmaceutical company, the company made significant progress in H1, including the removal of its 'B' share designation and a successful HKD 1.55 billion equity placement, bolstering capital reserves for its "dual-driver" strategy - The company is committed to creating value through a differentiated innovative medicine portfolio and building sustainable shareholder growth[41](index=41&type=chunk) - The **"dual-driver" strategy** focuses on organic pipeline growth via mRNA technology and synergistic effects through business expansion and in-licensing[41](index=41&type=chunk) - Nefecon®'s full-year sales are projected to reach **RMB 1.2 to 1.4 billion**, with total company full-year revenue expected to be **RMB 1.6 to 1.8 billion**[39](index=39&type=chunk)[40](index=40&type=chunk) [Product Pipeline](index=16&type=section&id=%E7%94%A2%E5%93%81%E7%AE%A1%E7%B7%9A) The company boasts a robust pipeline in renal, anti-infective, and autoimmune diseases, featuring first-in-class or best-in-class assets like approved Nefecon®, Yijia®, and Etrasimod, alongside clinical-stage candidates and advanced mRNA platform projects - The company's product pipeline includes first-in-class or best-in-class assets across renal, anti-infective, and autoimmune disease areas[43](index=43&type=chunk) Key Product Pipeline and Development Status | Molecule (Therapy) | Partner | Commercial Rights | Indication | R&D Progress | | :--- | :--- | :--- | :--- | :--- | | NEFECON® | Greater China, Singapore, South Korea | IgA Nephropathy | Approved in Mainland China, Macau, Hong Kong, Taiwan, South Korea, and Singapore | | Yijia® (Eravacycline) | Greater China, South Korea, Southeast Asia | Complicated Intra-abdominal Infections | Approved in Mainland China, Hong Kong, Taiwan, and Singapore | | Etrasimod | Greater China, South Korea, Singapore | Ulcerative Colitis | Approved in Macau, Hong Kong, and Singapore | | Cefepime-Taniborbactam | Greater China, South Korea, Southeast Asia | Complicated Urinary Tract Infections | Priority Review in Mainland China | | Zetomipzomib | Greater China, South Korea, Southeast Asia | Autoimmune Hepatitis | Phase 2a | | EVER001 (XNW1011) | Global | Membranous Nephropathy | Phase 1b/2a | | Personalized Cancer Vaccine | In-house R&D | Global | Oncology | IIT initiated | | Tumor-Associated Antigen Vaccine | In-house R&D | Global | Oncology | US IND approved | [Business Review](index=17&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7) This section reviews pipeline and commercialization progress, highlighting Nefecon®'s full approval across Asia, Etrasimod's Hong Kong approval and regulatory submissions, positive EVER001 Phase 1b/2a data, and significant advancements in proprietary mRNA cancer vaccines EVM16 and EVM14, with EVM14 achieving dual US and China filings - Nefecon® achieved **full approval** across all authorized regions, solidifying its cornerstone position as a first-line treatment for IgA nephropathy in Asia[46](index=46&type=chunk) - Etrasimod received new drug marketing approval in **Hong Kong SAR**, with applications accepted in South Korea and Taiwan, and **NMPA approval in mainland China expected in H1 2026**[46](index=46&type=chunk) - EVER001 Phase 1b/2a trial for primary membranous nephropathy showed positive data, with anti-PLA2R antibody levels decreasing by nearly **100%** and proteinuria levels by approximately **80%**[47](index=47&type=chunk) - Personalized mRNA cancer vaccine **EVM16 IIT** completed dosing for **9 patients**, with preliminary data expected in H2 this year[48](index=48&type=chunk) - Universal TAA mRNA vaccine candidate **EVM14** received **US FDA IND approval** and **China NMPA acceptance**, achieving dual US and China filings[48](index=48&type=chunk) [Pipeline Outlook](index=17&type=section&id=%E7%AE%A1%E7%B7%9A%E5%B1%95%E6%9C%9B) Nefecon® achieved full approval across Asia, solidifying its IgA nephropathy treatment status, Etrasimod gained Hong Kong approval and is under review in Korea and Taiwan, with mainland China approval expected in H1 2026, EVER001 showed positive Phase 1b/2a data, and mRNA cancer vaccines EVM16 and EVM14, along with self-generating CAR-T projects, made significant progress - Nefecon® achieved **full approval** across all authorized regions, solidifying its cornerstone position as a first-line treatment for IgA nephropathy in Asia, and promoting treatment standardization[46](index=46&type=chunk) - Etrasimod received new drug marketing approval in **Hong Kong SAR**, with applications accepted in South Korea and Taiwan, and **NMPA approval in mainland China expected in H1 2026**[46](index=46&type=chunk) - EVER001 Phase 1b/2a trial for primary membranous nephropathy showed positive data, with anti-PLA2R antibody levels decreasing by nearly **100%** and proteinuria levels by approximately **80%**[47](index=47&type=chunk) - Personalized mRNA cancer vaccine **EVM16 IIT** completed dosing for **9 patients**, with preliminary data expected in H2 this year[48](index=48&type=chunk) - Universal TAA mRNA vaccine **EVM14** received **US FDA IND approval** and **China NMPA acceptance**, with US clinical studies planned for **H2 2025**[48](index=48&type=chunk) [Commercialization](index=18&type=section&id=%E5%95%86%E6%A5%AD%E5%8C%96) In H1 2025, Nefecon® and Yijia® generated RMB 446 million in sales revenue, with Nefecon® experiencing rapid growth due to NRDL inclusion and expanded hospital coverage, Yijia® showing steady growth with increased hospital penetration, and Etrasimod initiating early use in Guangdong and local production - In **H1 2025**, **Nefecon®** and **Yijia®** generated **RMB 446 million** in sales revenue[50](index=50&type=chunk) - Nefecon®'s inclusion in the **NRDL** on **January 1, 2025**, led to rapid H1 sales growth and over **20,000 new patients**[50](index=50&type=chunk) - Nefecon® was recommended as the preferred causal treatment in the **"Chinese Clinical Practice Guidelines for Adult IgA Nephropathy and IgA Vasculitis (Pre-review Version)"**[51](index=51&type=chunk) - Yijia®'s penetration increased in approximately **300 core hospitals**, showing steady sales growth, with its China breakpoint approved by CDE and updated in the package insert[53](index=53&type=chunk) - Etrasimod is in early use in **9 medical institutions** in Guangdong via the "Hong Kong and Macao Medicine and Medical Device Connect" policy, and the Jiaxing factory launched localized production with an estimated annual capacity of **5 million bottles**[56](index=56&type=chunk) [Commercialization Outlook](index=21&type=section&id=%E5%95%86%E6%A5%AD%E5%8C%96%E5%B1%95%E6%9C%9B) In H2 2025, the company will accelerate commercialization and expand access to innovative therapies, with Nefecon® fully integrated into medical insurance and projected for RMB 1.2-1.4 billion in annual sales, Yijia® deepening hospital penetration, and Etrasimod advancing mainland China launch preparations - Nefecon® will achieve full medical insurance coverage in H2 and is expected to be included in the **2025 KDIGO IgA Nephropathy Guideline** and China's first IgA nephropathy clinical guideline[57](index=57&type=chunk) - Nefecon®'s production capacity expansion approval paves the way for significant H2 2025 sales growth, with full-year sales projected at **RMB 1.2 to 1.4 billion**[58](index=58&type=chunk) - Yijia® will continue deep penetration in core hospitals, targeting high-potential institutions and optimizing its CSO cooperation model[58](index=58&type=chunk) - Combined full-year revenue for **Nefecon®** and **Yijia®** is projected to reach **RMB 1.6 to 1.8 billion** in 2025[58](index=58&type=chunk) - Etrasimod's mainland China launch preparations are advancing, setting the stage for rapid market entry post-NMPA approval in **H1 2026**[59](index=59&type=chunk) [In-house R&D](index=21&type=section&id=%E8%87%AA%E4%B8%BB%E7%A0%94%E7%99%BC) H1 2025 marked a critical execution period for the company's "dual-driver" strategy and mRNA platform, with personalized mRNA cancer vaccine EVM16 completing dosing for 9 patients showing good immunogenicity, universal TAA mRNA cancer vaccine EVM14 achieving dual US and China filings and releasing GMP clinical samples, and the mRNA self-generating CAR-T platform yielding multiple preclinical validation results - The company successfully hosted the **"2025 Everest Medicines mRNA Innovation Technology Platform R&D Day,"** showcasing advancements in its proprietary AI-driven mRNA technology platform[60](index=60&type=chunk) - Personalized mRNA therapeutic cancer vaccine **EVM16 IIT** completed dosing for **9 patients**, showing good immunogenicity by eliciting specific T-cell responses even at low starting doses[62](index=62&type=chunk) - Universal TAA mRNA cancer vaccine **EVM14** achieved dual US and China filings and released the first batch of **GMP clinical trial samples**, validating the company's full-chain mRNA platform[63](index=63&type=chunk) - The mRNA self-generating CAR-T platform achieved multiple preclinical validation results, demonstrating efficacy in humanized mouse and non-human primate models, potentially revolutionizing traditional CAR-T therapies[64](index=64&type=chunk) - In **H2 2025**, personalized cancer vaccine **EVM16** is expected to complete Phase Ia enrollment, **EVM14** will start US dosing and may receive China IND approval, and the self-generating CAR-T platform is expected to identify clinical candidates[65](index=65&type=chunk) [Business Development](index=23&type=section&id=%E6%A5%AD%E5%8B%99%E6%8B%93%E5%B1%95) The 2025 business development strategy focuses on high clinical value, differentiated first-in-class or best-in-class assets in renal, autoimmune, and anti-infective diseases, seeking in-licensing opportunities for commercial or near-commercial assets, and global partnerships for early-stage assets like EVER001 and mRNA platform projects, while strategically increasing I-Mab equity to become its largest shareholder, deepening oncology immunotherapy - Business development focuses on high clinical value, differentiated first-in-class or best-in-class assets, prioritizing renal, autoimmune, and anti-infective diseases[66](index=66&type=chunk) - The company will seek in-licensed assets at commercial or near-commercial stages and actively pursue international collaboration for early-stage global assets[66](index=66&type=chunk)[67](index=67&type=chunk) - One-year follow-up data for primary membranous nephropathy patients in the **EVER001 (sibrotuzumab) Ib/IIa clinical trial** is expected in **September**[67](index=67&type=chunk) - mRNA-based therapeutic cancer vaccine projects **EVM16** and **EVM14** will yield key preliminary human data in **H2 this year** and **H1 next year**, respectively, supporting potential global collaborations[67](index=67&type=chunk) - The company strategically increased its stake in I-Mab to approximately **16.1%**, becoming its largest shareholder and advancing its global next-generation oncology immunotherapy pipeline[68](index=68&type=chunk) [Financial Review](index=24&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%A7) For the six months ended

Core Insights - The AI Fund Ping An Medical Health Mixed A (003032) reported a profit of 352 million yuan for the first half of 2025, with a weighted average profit per fund share of 1.0034 yuan [2] - The fund's net value growth rate was 57.41% during the reporting period, with a total fund size of 966 million yuan as of the end of June [2] - The fund focuses on long-term investments in pharmaceutical and medical stocks, with a current unit net value of 3.103 yuan as of September 3 [2] Performance Metrics - As of September 3, the fund's one-year cumulative net value growth rate was 111.92%, ranking 5th out of 136 comparable funds [5] - The fund's three-month net value growth rate was 32.83%, ranking 29th out of 138 comparable funds [5] - The fund's three-year Sharpe ratio was 0.4698, ranking 15th out of 105 comparable funds [25] Investment Strategy - The fund manager emphasized the importance of sub-industry prosperity in investment strategy, focusing on companies with valuation advantages in the innovative drug sector [2] - The fund's top ten holdings include companies such as CloudTop New Medicine, Innovent Biologics, and BeiGene, indicating a concentrated investment approach [40] Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately -202.85, compared to the industry average of 120.96 [9] - The weighted average price-to-book (P/B) ratio was about 7.89, while the industry average was 4.07 [9] - The weighted average price-to-sales (P/S) ratio was approximately 14.98, compared to the industry average of 6.52 [9] Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.17%, while the weighted average net profit growth rate was -0.21% [16] - The fund's weighted annualized return on equity was -0.04% [16] Fund Composition - As of June 30, 2025, the fund had 24,900 holders, with a total of 395 million shares held [34] - Institutional investors held 64.36% of the fund's shares, while individual investors accounted for 35.64% [34] - The fund's turnover rate for the last six months was approximately 143.02%, consistently below the industry average [37]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 雲頂新耀有限公司 | | | | 呈交日期: | 2025年9月4日 | | | I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01952 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | ...

Group 1 - The core viewpoint of the article highlights a collective decline in Hong Kong's innovative drug concept stocks on September 4, with significant drops in various companies [1] Group 2 - Zai Lab experienced a decline of over 10% [1] - Hengrui Medicine, Genscript Biotech, and Cloudmed fell by more than 5% [1] - WuXi AppTec dropped over 4%, while Innovent Biologics, WuXi Biologics, and Hansoh Pharmaceutical decreased by more than 3% [1]

Group 1: Strategy and Market Outlook - The report suggests a strong allocation towards precious metals, particularly gold, and recommends overweighting Hong Kong stocks benefiting from potential Federal Reserve rate cuts, while maintaining positions in A-shares with a balanced focus on resources and technology growth [1][10] - The report highlights the acceleration of de-dollarization and challenges to the independence of the Federal Reserve, which may lead to increased demand for gold as a safe asset [8][9] Group 2: Motorcycle Industry Insights - The domestic large-displacement motorcycle penetration rate is continuously increasing, with significant growth potential for Chinese motorcycle manufacturers in the global market, particularly in large-displacement segments [2][12] - The report indicates that from 2020 to 2024, the sales of large-displacement motorcycles in China are expected to grow from approximately 140,000 units to 400,000 units, with a CAGR of 30% [13] - Exports are becoming a crucial growth driver for Chinese motorcycle manufacturers, with the export volume of motorcycles expected to increase significantly, particularly in the large-displacement category [14][15] Group 3: Company-Specific Analysis - Tengya Precision (301125.SZ) is expected to achieve a net profit of 44 million, 149 million, and 231 million yuan from 2025 to 2027, with corresponding PE ratios of 64.2, 18.9, and 12.2, indicating strong growth potential [5][22] - Zhongke Shuguang (603019.SH) is projected to have a net profit of 2.712 billion, 3.355 billion, and 3.762 billion yuan from 2025 to 2027, with a year-on-year growth of 41.9%, 23.7%, and 12.2% respectively [6][24] - The report emphasizes the robust growth of the AI and smart inspection business for Zeyu Intelligent (301179.SZ), with expected net profits of 222 million, 266 million, and 322 million yuan from 2025 to 2027 [37][39] Group 4: Investment Recommendations - Key recommendations include focusing on leading motorcycle manufacturers such as Chunfeng Power, Longxin General, and Qianjiang Motorcycle, which are expected to benefit from the growing global demand for large-displacement motorcycles [3][16] - The report suggests maintaining a "buy" rating for Tengya Precision, Zhongke Shuguang, and Zeyu Intelligent based on their growth prospects and market positioning [22][24][39]

Core Viewpoint - The company has demonstrated strong sales growth for its product, Naisfukang, following capacity expansion, leading to an upward revision of sales guidance and reflecting confidence in clinical data and commercialization capabilities [1][2] Group 1: Sales Performance - In the first half of 2025, the company's revenue increased by 48% year-on-year to 446 million RMB, with Naisfukang sales growing by 81% to 303 million RMB [1] - After capacity constraints were resolved, Naisfukang's sales surged to 522 million RMB in August, contributing to a total sales figure of 825 million RMB from January to August [1] - The management has raised the annual sales target for Naisfukang to 1.2-1.4 billion RMB, with total product sales expected to reach 1.6-1.8 billion RMB [1] Group 2: Financial Outlook - The company expects to achieve operational breakeven in the second half of 2025, earlier than previously anticipated [1] - The net loss for the first half of 2025 narrowed significantly by 61% to 250 million RMB, attributed to strong sales performance and stable SG&A expense ratios [1] Group 3: Product Pipeline and Future Prospects - The company is set to commercialize its third product, Aicuo Mod, which is anticipated to be approved in the first half of 2026 for ulcerative colitis, with a projected peak sales of 5 billion RMB [2] - The self-developed pipeline includes EVER001, targeting autoimmune kidney diseases, with global sales peak expected to exceed 10 billion RMB [2] - The company has revised its revenue forecasts for 2026-2027 upwards by 16-18%, reflecting optimism in operational expense ratios and potential catalysts in the pipeline [2] Group 4: Valuation and Investment Recommendation - The target price has been raised to 84 HKD from 72.5 HKD, corresponding to a 2.1 times revenue peak sales multiple [2] - The current valuation remains attractive, with multiple catalysts expected in the second half of 2025 and 2026, including product approvals and commercialization efforts [2]